Novel Synthetic Nucleic Acid Technology Development (R43/R44) (2022)

Written by startup news

February 1, 2022

The funding opportunity announcement grant applications to develop novel technologies. Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. If interested, you can apply for this technology grant.

You can check out the Eligibility Criteria and other Details mentioned below before applying for this technology grant.

Sponsoring Agency: Department of Health and Human Services 

Type of Fund: Grant

Deadline: February 4, 2022

Details:

Novel Synthetic Nucleic Acid Technology Development Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications from small businesses to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids.

The goal is to improve the quality, capabilities, and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Large progress in this area has the potential to catalyze scientific advances relevant to the mission of NIH, NHGRI, and the field of genomics.

Applicants may propose to develop novel complete synthesis and/or synthetic constructs systems, investigate challenges underlying key novel system components, or propose substantive improvements of at least an order of magnitude improvement to existing commercial systems. Exploration of methods other than those currently commercially in use is highly encouraged.

Eligibility Criteria

You are eligible if:

Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria:

  • Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials, or labor;
  • Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust, or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture;
  • Has, including its affiliates, not more than 500 employees.

More Information 

In accordance with guidance from the SBA, HHS, including NIH, SBIR/STTR Programs are implementing the Phase II to Phase III Commercialization Rate benchmark for Phase I applicants, as required by the SBIR/STTR Reauthorization Act of 2011. The Commercialization Rate Benchmark was published in a Federal Register notice on August 8, 2013 (78 FR 48537).

This requirement applies to companies that have received more than 15 Phase II awards from all agencies over the past 10 years, excluding the two most recently completed Fiscal Years. Companies that meet this criterion must show an average of at least $100,000 in revenues and/or investments per Phase II award or at least 0.15 (15%) patents per Phase II award resulting from these awards. This requirement does not apply to companies that have received 15 or fewer Phase II awards over the 10 year period, excluding the two most recently completed Fiscal Years.

Information on Phase II to Phase III Commercialization Benchmark is available at SBIR.gov.

Applicants to this FOA that may have received more than 15 Phase II awards across all federal SBIR/STTR agencies over the past ten (10) years should, prior to application preparation, verify that their company’s Commercialization Benchmark on the Company Registry at SBIR.gov meets or exceeds the benchmark rate listed above.

Applicants that fail this benchmark will be notified by SBA annually and will not be eligible to apply for New Phase I, Fast-track, or Direct Phase II (if applicable) awards for a period of one year.

Funding Information 

Total funding support (direct costs, indirect costs, fee) normally may not exceed $256,580 for Phase I awards and $1,710,531 for Phase II awards. NIH has received a waiver from SBA, as authorized by statute, to exceed these total award amount hard caps for specific topics. Navigate to the “Program Descriptions and Research Topics” document, Appendix A or the current “SBA approved topics list for budget waivers”.

Applicants are strongly encouraged to contact program officials prior to submitting any application in excess of the hard caps listed above and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for the completion of the research project.

According to statutory guidelines, award periods normally may not exceed 6 months for Phase I and 2 years for Phase II. Applicants are encouraged to propose a project duration period that is reasonable and appropriate for the completion of the research project.

For more information, visit here.

You May Also Like…

0 Comments

Submit a Comment

Your email address will not be published.